BLAINJECTIONINJECTABLE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) by Roche is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2024.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TECENTRIQ HYBREZA is a fixed-dose combination of atezolizumab (a PD-1 blocking antibody) and hyaluronidase-tqjs, enabling subcutaneous delivery of the checkpoint inhibitor. It is indicated for cancers where PD-1 blockade is therapeutic, with the hyaluronidase component improving patient convenience by reducing infusion time and enabling self-administration. The drug works by releasing PD-1 checkpoint brakes on T cells, restoring anti-tumor immunity.
Growth
Early-stage growth phase product recently approved; commercial team is scaling market penetration against established competitors in a crowded PD-1 checkpoint class.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TECENTRIQ HYBREZA positions you in a high-visibility oncology franchise amid intense competitive pressure; career trajectory depends on successful market capture against established players. Early-stage launch roles offer visibility and upside potential, but eventual lifecycle decline (typical for biologic combinations) means strategic transition planning is essential 3–5 years post-launch.
Brand Manager
Worked on TECENTRIQ HYBREZA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.